Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Tissue Repair Ltd ( (AU:TRP) ).
Tissue Repair reported accelerated recruitment in its U.S. Phase 3 trial of TR987 for chronic wounds, with 64 patients randomised and a target of about 100 patients by September 2026 to enable interim analysis. The company is also advancing a device-based regulatory strategy for TR Pro+, pursuing 510(k) clearance and CE marks that could leverage existing trial data and potentially benefit from favourable U.S. reimbursement changes.
Commercially, TR Pro+ sales grew in the March quarter to more than 9,000 tubes, and the company is completing its largest production run of around 78,000 tubes ahead of a broader SKU rollout expected to lift monthly volumes. Tissue Repair ended March with $6.657 million in cash, quarterly operating outflows of $1.684 million, an expected R&D tax rebate, and an estimated funding runway of about four quarters as it continues to balance R&D investment with commercialisation efforts.
More about Tissue Repair Ltd
Tissue Repair Limited is an ASX-listed biotechnology company focused on treatments for chronic wounds, dermatology and aesthetic and medical procedures. Its lead assets include TR987, a chronic wound therapy in Phase 3 trials, and TR Pro+, a topical product sold into aesthetic and medical markets with growing distribution through partners such as Advanced Cosmeceuticals.
Average Trading Volume: 75,557
Technical Sentiment Signal: Sell
Current Market Cap: A$9.37M
Find detailed analytics on TRP stock on TipRanks’ Stock Analysis page.